Epstein Secrets

Melanoma Research Alliance December 22, 2017 Mr. Jeffrey Epstein 9 East 71st Street New York, NY 10021-4102 Delivered via email: [email protected] Dear Mr. Epstein, On behalf of the Melanoma Research Allia

h Alliance December 22, 2017 Mr. Jeffrey Epstein 9 East 71st Street New York, NY 10021-4102 Delivered via email: [email protected] Dear Mr. Epstein, On behalf of the Melanoma Research Alliance (MRA), it is my pleasure to update you on the progress of Ian Watson, PhD, of McGill University, who i

lanoma Research Alliance December 22, 2017 Mr. Jeffrey Epstein 9 East 71st Street New York, NY 10021-4

Delivered via email: [email protected] Dear Mr. Epstein, On behalf of the Melanoma Research Alliance (MR

influencing the production of a molecule that is a major target in several approved immune "checkpoint inhibitor" therapies, such as pembrolizumab (Keytruda). Dr. Watson and his research team are currently collaborating with several oncologists, dermatology pathologists, and surgeons at McGill Universit

From: John Brockman < Sent: Monday, February 6, 2017 8:34 PM To: Jeffrey Epstein Subject: sorry I missed your call JE, --Last week was misery...On Tuesday, Katinka's' younger brother, =onathan Matson, was planning on flying in

: Monday, February 6, 2017 8:34 PM To: Jeffrey Epstein Subject: sorry I missed your call JE, --Last

frey Epstein Subject: sorry I missed your call JE, --Last week was misery...On Tuesday, Katinka's'

< Sent: Monday, February 6, 2017 8:34 PM To: Jeffrey Epstein Subject: sorry I missed your call JE,

finally caught up to him: "I have run out of standard treatments. Chemo is getting less effective =ith increasing side effects. There is a new drug Keytruda it has been =pproved for some cancers but is still experimental for prostate cancer. =ttps://prostatecancernewstoday.com/pembrolizumab-immune-therap

From: Richard Kahn To: Jeffrey Epstein [email protected]> Subject: Mrk Date: Wed, 02 Sep 2015 10:52:53 +0000 PivIRK Chart MRK data by YCharts 4. Merck & Co. (MRK) Credit Suisse R

From: Richard Kahn To: Jeffrey Epstein [email protected]> Subject: Mrk Date: Wed,

From: Richard Kahn To: Jeffrey Epstein [email protected]> Subject: Mrk Dat

yst: MRK's Januvia franchise will likely feel pressure from the positive EMPA-REG OUTCOME data but we expect MRK to get a boost from FDA approval of Keytruda in 2nd line NSCLC soon (FDA action date Oct 2) and its HCV doublet grazoprevir/elbasvir by early next year (FDA action date Jan 28). TheStreet Rati